SLC9A9 and neoplasm: Following neo-adjuvant chemotherapy and tumor resection, GBM patients overexpressing NHE9 remained disease free for ~11 months with median survival of only 16 months compared to patients with unaltered expression of NHE9 who remained disease free for ~34 months with median survival of ~59 months [7].